What Is a Patent Cliff?
The patent cliff explained, why billions in drug revenue disappear when patents expire, and what it means for patients and investors.
Read guide →Updated April 2026 · USPTO + FDA Orange Book
Learn: Patents, Generics, and the Patent Cliff
Plain-English guides to U.S. drug patents, exclusivity timelines, and how generic competition arrives — sourced from USPTO patent records and the FDA Orange Book.
Why Patent Timing Matters
Every prescription drug sold in the United States traces back to a stack of legal protections — patents granted by the U.S. Patent and Trademark Office and exclusivities awarded by the FDA. When those protections expire, generic manufacturers can step in with chemically identical versions, and prices typically fall by 80–95% within 12 to 18 months. That single mechanism is the largest cost-control lever in U.S. pharmaceutical pricing, and it is the focal point of this site.
For investors, the patent cliff is a quarterly earnings event — Lipitor, Plavix, Humira each took down billions in branded revenue when their cliffs hit. For patients and prescribers, expiration timing is the difference between a $400 monthly co-pay and a $20 one. For generic manufacturers and biosimilar developers, the Paragraph IV calendar determines which products to challenge first. These guides explain the rules of that calendar.
Guides
How Long Do Drug Patents Last in the US?
20 years from filing, but effective market exclusivity is much shorter. Here is how patent term, extensions, and regulatory exclusivity work.
Read guide →Loss of Exclusivity vs. Patent Expiry
Patent expiry and loss of exclusivity are not the same thing. One is a legal term, the other determines when generics actually enter.
Read guide →Paragraph IV Certification Explained
How generic manufacturers challenge drug patents, the ANDA process, 30-month stay, and 180-day exclusivity.
Read guide →The FDA Orange Book Explained
The official database of approved drugs, their patents, and exclusivity periods, how to read it and what it means.
Read guide →Biosimilars vs. Generics
Why biosimilars cost more, take longer to develop, and produce smaller price drops than traditional generics.
Read guide →How to Use These Guides
Start with What Is a Patent Cliff? for the core concept, then move to How Long Do Drug Patents Last for the math behind a 20-year term. The Loss of Exclusivity guide is the one most people get wrong on first reading — patent expiry and exclusivity loss are different events, and the gap between them can run several years on a single product.
For the procedural side, Paragraph IV Certification explains how the first generic challenger captures 180 days of exclusivity, and The FDA Orange Book shows how to look up listed patents for any approved drug. Biosimilars vs. Generics covers why biologic drugs follow a different — and slower — path to competition than small-molecule drugs.
Authoritative Sources
All of the rules summarized in these guides come directly from federal sources. The USPTO patent search is the system of record for granted patents. The FDA Orange Book is the system of record for approved drug exclusivities. The USPTO Open Data Portal and Google Patents both expose USPTO records through different interfaces. Where these guides simplify, the original federal documents always govern.
Frequently Asked Questions
What is the difference between a patent cliff and loss of exclusivity?
A patent cliff is the cluster of revenue declines that happens when a blockbuster drug — or a portfolio of them — reaches the end of its patent protection within a short window. Loss of exclusivity is the broader legal moment when a manufacturer can no longer block generic competition under any combination of patent and FDA-granted exclusivities. A drug can lose exclusivity even while one of its patents is still legally valid, because regulatory exclusivities and method-of-use patents work in parallel. The patent expiry date in the FDA Orange Book is just one input.
Where does the data on this site come from?
PatentCliff combines USPTO patent records pulled through the PatentsView and Open Data APIs with FDA Orange Book listings of approved drug products and their patent and exclusivity periods. Both data sources are public-domain U.S. government data with no licensing restrictions. Patent expirations are calculated as 20 years from earliest non-provisional filing, adjusted where the USPTO has issued a Patent Term Adjustment or Patent Term Extension on the record.
How long does a U.S. patent actually protect a drug?
A U.S. utility patent runs 20 years from its earliest non-provisional filing date. For pharmaceuticals, the effective market exclusivity is usually 7–14 years because clinical trials and FDA review consume much of the 20-year window. Patent Term Extensions under the Hatch-Waxman Act can restore up to five years of patent life lost to regulatory review, and FDA-granted exclusivities (5-year new chemical entity, 7-year orphan, 6-month pediatric) can stack on top of the patent term to delay generic entry further.
What is a Paragraph IV challenge?
A Paragraph IV certification is a generic manufacturer's formal claim, filed as part of an Abbreviated New Drug Application (ANDA), that the brand drug's listed patent is either invalid or will not be infringed by the generic version. Filing a Paragraph IV triggers a 45-day window for the brand to sue, which then triggers an automatic 30-month stay on FDA approval of the generic. The first generic filer to win or settle gets 180 days of generic-market exclusivity — a powerful incentive that drives most early generic launches in the U.S.
What is the FDA Orange Book and why does it matter?
The FDA Orange Book — formally Approved Drug Products with Therapeutic Equivalence Evaluations — is the federal registry of every approved drug product in the United States, the patents the manufacturer has listed for it, and the regulatory exclusivities the FDA has granted. Generic manufacturers must reference an Orange Book entry when filing an ANDA, and Orange Book patent listings are what determine when a Paragraph IV challenge can be brought. It is updated continuously and is the single most important public document for tracking U.S. drug exclusivity timelines.
Sources: U.S. Patent and Trademark Office (PatentsView, Open Data Portal); U.S. Food and Drug Administration (Orange Book). Both are public-domain federal datasets.
Last updated 2026-04-10.